Publication:
Immunogenicity and Safety Profile of Typhoid Conjugate Vaccine (Vi-DT) Among Nepali Children

Simple item page
creativeworkseries.issn1999-6217
dc.contributor.authorAdhikari, Santosh
dc.contributor.authorRai, Ganesh Kumar
dc.contributor.authorChapagain, Ram Hari
dc.contributor.authorGiri, Bishnu Rath
dc.contributor.authorJoshi, Prakash
dc.contributor.authorShrestha, Nisha Jyoti
dc.contributor.authorManandhar, Bina Prajapati
dc.contributor.authorTamang, Suresh Man
dc.contributor.authorMaharjan, Jessica
dc.contributor.authorThapaliya, Bibesh
dc.contributor.authorGupta, Birendra Prasad
dc.contributor.authorKim, Deok Ryun
dc.contributor.authorVemula, Sridhar
dc.contributor.authorSahastrabuddhe, Sushant
dc.contributor.authorSaluja, Tarun
dc.date.accessioned2025-07-11T07:25:31Z
dc.date.available2025-07-11T07:25:31Z
dc.date.issued2025
dc.descriptionSantosh Adhikari Kanti Childrens Hospital, 2 National Academy of Medical Sciences, 3 International Vaccine Institute. https://orcid.org/0000-0003-4345-6131 Ganesh Kumar Rai Kanti Childrens Hospital, National Academy of Medical Sciences. Ram Hari Chapagain International Vaccine Institute. Bishnu Rath Giri Kanti Childrens Hospital. Prakash Joshi Kanti Childrens Hospital, National Academy of Medical Sciences. Nisha Jyoti Shrestha Kanti Childrens Hospital, National Academy of Medical Sciences. Bina Prajapati Manandhar Kanti Childrens Hospital, National Academy of Medical Sciences. Suresh Man Tamang Kanti Childrens Hospital. Jessica Maharjan Kanti Childrens Hospital. Bibesh Thapaliya Kanti Childrens Hospital. Birendra Prasad Gupta International Vaccine Institute. Deok Ryun Kim International Vaccine Institute. Sridhar Vemula International Vaccine Institute. Sushant Sahastrabuddhe International Vaccine Institute. Tarun Saluja International Vaccine Institute.
dc.description.abstractBackground: Typhoid fever remains a major concern in tropical countries. The availability of an effective vaccine could be an important inclusion to currently available interventions. We reported on our evaluation of the immunogenicity and safety of the typhoid conjugate vaccine (Vi-DT) among Nepali children. Methods: The study was an observer blinded, active controlled, randomized phase III clinical trial in children above 6 months and less than 18 years old. Three different lots of Vi-DT(Vi- Diptheria Toxoid); test vaccine and Vi-TT ( Vi-Tetanus Toxoid); comparator vaccines were administered to eligible children. Seroconversion was assessed with blood samples collected at baseline and 4 weeks after the vaccination. A rise of at least 4-fold vi-antibody titer from the baseline was used to indicate positive seroconversion. Data on solicited and unsolicited adverse events were collected. Results: Four hundred and eighty-eight children participated in the study. Seroconversion rate was 98.61% and 98.36% among participants who received Vi-DT and Vi-TT vaccines respectively. One immediate adverse event was observed only for Vi-DT group. One hundred forty-two and 66 solicited AEs within 7 days were observed with test and comparator vaccine respectively. Unsolicited AEs within 28 days were 125 for test vaccine compared and 77 for the comparator vaccine. Two SAEs were reported which were Not- related to study vaccine. Conclusions: The overall seroconversion in Vi DT vaccine was non inferior to the comparator vaccine and the safety profile of the vaccine was good without any life-threatening events. Keywords: Immunogenicity; Nepal; safety profile; typhoid conjugate vaccine; Vi-DT
dc.identifierhttps://doi.org/10.33314/jnhrc.v23i01.5251
dc.identifier.urihttps://hdl.handle.net/20.500.14572/108
dc.language.isoen_US
dc.publisherNepal Health Research Council
dc.titleImmunogenicity and Safety Profile of Typhoid Conjugate Vaccine (Vi-DT) Among Nepali Children
dc.typeArticle
dspace.entity.typePublication
local.article.typeOriginal Article
oaire.citation.endPage88
oaire.citation.startPage82
relation.isJournalIssueOfPublication710a5a58-3a9b-4cdc-9898-5e7769f7ec25
relation.isJournalIssueOfPublication.latestForDiscovery710a5a58-3a9b-4cdc-9898-5e7769f7ec25
relation.isJournalOfPublication40bd2739-8b19-447c-be60-723a1bdd1dcd

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
webmaster,+Jan_Mar_2025+Issue-4-218-82-88.pdf
Size:
649.48 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.86 KB
Format:
Item-specific license agreed to upon submission
Description:
Download

Collections

Publications

Connect with us

Nepal Health Research Council © 2023
Ramshah Path, Kathmandu Nepal P.O.Box 7626